Market cap
₹2,164 Cr
Revenue (TTM)
₹-- Cr
P/E Ratio
--
P/B Ratio
0.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹0 Cr
-
ROE
0 %
-
ROCE
-2.9 %
-
Industry P/E
60.11
-
EV/EBITDA
-8013.3
-
Debt to Equity
-1.8
-
Book Value
₹-2.1
-
EPS
₹-0.1
-
Face value
10
-
Shares outstanding
54,567,765
10 Years Aggregate
CFO
₹609.41 Cr
EBITDA
₹973.84 Cr
Net Profit
₹663.74 Cr
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Claris Lifesciences
| 11.3 | 1.7 | 13.0 | 24.4 | 13.7 | 16.1 | -- |
|
BSE Sensex*
| -11.2 | -4.2 | -10.2 | -8.7 | 7.0 | 8.4 | 11.3 |
|
BSE Healthcare#
| 9.5 | 9.4 | 9.8 | 12.1 | 27.6 | 14.5 | 11.8 |
|
Company
|
2017
|
2016
|
2015
|
2014
|
|---|---|---|---|---|
|
Claris Lifesciences
| 11.3 | 48.4 | 19.0 | -9.1 |
|
BSE Sensex
| 27.9 | 1.9 | -5.0 | 29.9 |
|
BSE Healthcare
| 0.5 | -12.9 | 15.1 | 47.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Claris Lifesciences
|
396.6 | 2,163.9 | 13.9 | -0.3 | -434.7 | 0 | -- | 0.7 |
| 2,886.5 | 23,622.7 | 1,339.4 | 356.4 | 33.2 | 23.2 | 66.3 | 14.3 | |
| 428.4 | 16,429.4 | 2,268.6 | 150.1 | 10.6 | 5.4 | 91.7 | 4.2 | |
| 766.5 | 18,987.4 | 5,365.6 | 595.0 | 16.6 | 13.3 | 31.9 | 3.7 | |
| 1,130.9 | 20,272.6 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 13 | 2.3 | |
| 1,854.5 | 21,250.8 | 1,421.6 | -73.8 | 1.8 | -1.1 | -- | 3.6 | |
| 173.2 | 23,029.2 | 8,869.1 | -383.1 | 1.0 | -4.2 | -- | 2.8 | |
| 984.5 | 16,251.7 | 1,284.3 | 134.4 | -- | 30.7 | 121 | 13.3 | |
| 471.4 | 19,016.9 | 3,738.7 | 316.7 | 12.5 | 7.5 | 60 | 3.9 | |
| 1,620.2 | 26,359.5 | 3,373.0 | 199.0 | 12.6 | 5.9 | 123.8 | 5.3 |
Shareholding Pattern
View DetailsNews & Analysis
All News
1 min read•By Research Desk
About Claris Lifesciences
Wholesale of pharmaceutical and medical goods
-
Incorporated
1994
-
Chairman
Surrinder Lal Kapur
-
Managing Director
Arjun Handa
-
Headquarters
Ahmedabad, Gujarat
-
Website
Looking for more details about Claris Lifesciences Ltd.’s IPO? Explore our IPO Details page.
Annual Reports
Announcements
View AnnouncementsAnnouncement under Regulation 30 (LODR)-Updates
12-Mar-2018Announcement under Regulation 30 (LODR)-Updates
12-Mar-2018Announcement under Regulation 30 (LODR)-Updates
22-Feb-2018No News & Announcements are available.
FAQs for Claris Lifesciences
What is the current share price of Claris Lifesciences Ltd Today?
The share price of Claris Lifesciences Ltd is ₹396.55 (BSE) as of 14-Mar-2018 IST. Claris Lifesciences Ltd has given a return of 13.7% in the last 3 years.
What is the current PB & PE ratio of Claris Lifesciences Ltd?
Since, TTM earnings of Claris Lifesciences Ltd is negative, P/E ratio is not available.
The P/B ratio of Claris Lifesciences Ltd is 0.74 times as on 14-Mar-2018, a 81 discount to its peers’ median range of 3.92 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
0.00
|
0.00
|
|
2020
|
0.00
|
0.00
|
|
2019
|
0.00
|
0.00
|
|
2018
|
127.31
|
3,071.96
|
|
2017
|
15.91
|
1.71
|
What is the 52 Week High and Low of Claris Lifesciences Ltd?
The 52-week high and low of Claris Lifesciences Ltd are Rs -- and Rs -- as of 20-May-2026.
What is the market cap of Claris Lifesciences Ltd?
Claris Lifesciences Ltd has a market capitalisation of ₹ 2,164 Cr as on 14-Mar-2018. As per SEBI classification, it is a company.
Should I invest in Claris Lifesciences Ltd?
Before investing in Claris Lifesciences Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.